Gilead, JAKed About Cancer Research, Buys YM BioScienses
This article was originally published in The Pink Sheet Daily
Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.
You may also be interested in...
With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.
Bispecific antibodies can be developed using many different formats for multiple therapeutic areas (see related story, (Also see "Is The Time Finally Right For Bispecific Antibodies?" - Pink Sheet, 16 Apr, 2013.)). Big pharmas have inked deals with modest upfront payments to explore the use of a variety of technology applications.
Gilead’s looming entrance into the increasingly competitive myelofibrosis market doesn’t phase Incyte executives, who remain upbeat about their first-in-class MF drug Jakafi. More than a year after its launch in November 2011, they point to new data demonstrating the drug’s overall survival benefits and greater clarity around optimal titration.